Matz, M; Coleman, MP; Sant, M; Chirlaque, MD; Visser, O; Gore, M; Allemani, C; & the CONCORD Working Group, (2016) The histology of ovarian cancer: worldwide distribution and implications for international survival comparisons (CONCORD-2). Gynecologic oncology. ISSN 0090-8258 DOI: https://doi.org/10.1016/j.ygyno.2016.10.019

Downloaded from: http://researchonline.lshtm.ac.uk/3221365/

DOI: 10.1016/j.ygyno.2016.10.019

Usage Guidelines

Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alternatively contact researchonline@lshtm.ac.uk.

Available under license: http://creativecommons.org/licenses/by-nc-nd/2.5/
Supplementary Figure 1

N=793,098 women (aged 15-99 years) registered with ovarian cancer during 1995-2009 in 61 countries

N=780,026 (98.4%)

Borderline tumours or haematopoietic morphology (13,072)

N=779,215 (98.2%)

Tumours morphologically verified, but unknown ICD-O-3 morphology code or morphology code not in ICD-O-3 code (811)

N=721,209 (90.9%)

Tumours not morphologically verified, or unknown if morphologically verified, with non-specific or unknown ICD-O-3 morphology (58,006)

N=695,435 (87.7%)

Tumours registered in registries for which survival estimates were considered less reliable (25,774)

N=682,466 (86.1%)

Women registered in countries with a high percentage of tumours of non-specific morphology (12,969)

N=681,759 women (86.0%) in 51 countries

Women registered in countries from which fewer than 100 women were available for analysis in a given calendar period (707 women, 12 countries)
Supplementary Figure 3

US registries (n=94,702)

Canada* (n=12,196)
Supplementary Figure 5

Australian registries (n=4,954)

New Zealand* (n=1,432)

- Type II
- Type I
- Germ cell
- Sex cord-stromal
- Other specific
- Non-specific